For decades, Big Food has been marketing products to people who can’t seem to stop eating, and now, suddenly, they can. The active ingredient in new drugs like Ozempic, Wegovy and Zepbound mimics a natural hormone that slows digestion and signals fullness to the brain. Around seven million Americans take these drugs, but estimates from Morgan Stanley suggest that number could increase to 24 million within the next decade. More than 100 million American adults are obese, and the drugs may eventually be rolled out to people who don’t have diabetes or obesity, as they seem to tame addictions beyond food — appearing to make cocaine, alcohol and cigarettes more resistible. Research is at an early stage, but the drugs may also cut the risk of stroke, heart and kidney disease, Alzheimer’s and Parkinson’s. Major food companies are scrambling to research the impact of the drugs on their brands — and figure out how to adjust. But for Mattson, which has invented products for the nation’s biggest food conglomerates for nearly 50 years, the Ozempic threat could be a boon.
This is A.O.
scott.
I'm a critic at the New York Times.
What I do and what the other critics here do is part of the same project that all of the journalists at the New York Times work on every day to give you clarity and perspective and above all, a deeper understanding of the world.
When you subscribe to the New York Times, it's not just here are the headlines, but here's the way everything fits together.
If you'd like to subscribe, Please go to nytimes.com subscribe.
Hi, my name's Thomas Weber, and I'm a contributor to the New York Times Magazine.
Ozempic, Wegovy, Mounjaro, Zepp Bound.
They're some of the brand names for weight loss drugs called GLP1 agonists.
In a nutshell, GLP1s reduce people's appetites.
We know they mimic the hormone that signals fullness to the brain.
But a couple of scientists I spoke to speculated that GLP1 drugs may also regulate the amount of dopamine that the brain releases.
And so when it does that, the drugs make foods that have been engineered to trigger the dopamine hit less appealing.
But researchers have also discovered something interesting about GLP1s.
They change the kinds of foods that people are interested in eating.
So instead of packaged, processed foods, many users tend to gravitate towards fresh fruits and vegetables.
So for this week's Sunday read, which you'll hear in a moment, I wrote about how drugs like Ozempic have the potential to disrupt, even upend the packaged food industry.
Early one morning last August, my reporting brought me to a glassy airy office building in the Bay Area, to the headquarters of a company called Mattson.
Matteson basically invents packaged foods and pitches them to the biggest food and drink companies in the world.
I passed display cases of prototypes from years past.